

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: *Cuttitta et al.*

Patent No. 7,462,593

Issued: December 9, 2008

Application No. 10/529,116

Filed: March 24, 2005

Confirmation No. 6564

FILED VIA EFS

For: A NEW TARGET FOR ANGIOGENESIS
AND ANTI-ANGIOGENESIS THERAPY

Examiner: Christine J. Saoud

Art Unit: 1647

Attorney Reference No. 4239-67026-06

FILED VIA ELECTRONIC FILING SYSTEM
COMMISSIONER FOR PATENTS

REQUEST FOR CERTIFICATE OF CORRECTION

The following printing errors were noted in comparing the printed patent with the papers in the attorneys' files:

On the Cover:

Page 1, above (*), Field (73) is missing. The name of the Assignee should read --The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services--.

Page 1, Field (56) under FOREIGN PATENT DOCUMENTS, a cited reference is missing, which should read --WO 00/69900 11/2000--.

Page 1, Field (56) under Other Publications, "NH₂-terminal" should read --NH₂-terminal--.

Page 1, Field (56) under Other Publications, "Gelatinases" should read --Gelatinases--.

Page 2, Field (56) under Other Publications, "Adrenomedulling" should read --Adrenomedullin--.

In the Specification:

In column 2, lines 34-35, “for use in treating retinopathy” is a repeated phrase that should be deleted.

In column 3, line 19, “ $p < 0.001$ ” should read -- $p < 0.001$ --.

In column 3, line 47, “ $0.01 > p > 0.001$ ” should read -- $0.01 > p > 0.001$ --.

In column 3, line 56, “angiogenesis” should read --angiogenesis--.

In column 4, lines 35-41, “PGDF” should read --PDGF--.

In column 4, lines 42-43, “18 S RNA” should read --18 S RNA--.

In column 4, line 42, “prier” should read --primer--.

In column 6, line 2, “Ophthalmol.” should read --Ophthalmol.--.

In column 7, line 39, “compliment” should read --complement--.

In column 7, line 51, “complimentary” should read --complementary--.

In column 7, line 56, “membrances” should read --membranes--.

In column 8, line 19, “arthritis considered” should read --arthritis is considered--.

In column 9, line 27, “tansyocardial” should read --transmyocardial--.

In column 10, line 41, “defect Particular” should read --defect. Particular--.

In column 11, line 7, “Ophthalmol.” should read --Ophthalmol.--.

In column 11, line 31, “separated produced” should read --separated, produced--.

In column 11, line 41, “term Thus” should read --term. Thus--.

In column 11, line 60, “and death and death” should read --and death--.

In column 12, line 35, “deoxyribose) linked” should read --deoxyribose)) linked--.

In column 13, line 20, “VFGF” should read --VEGF--.

In column 13, line 43, “mannitol lactose” should read --mannitol, lactose--.

In column 13, line 54, “neoplasm “Treatment”” should read --neoplasm.
“Treatment”--.

In column 14, lines 59-60, “dot-hike” should read --dot-like--.

In column 15, line 49, “Altschnul” should read --Altschul--.

In column 16, line 42, “advancements” should read --advancement--.

In column 16, line 48, “body weight The” should read --body weight. The--.

In column 16, line 63, “disulphide” should read --disulfide--.

In column 18, lines 2-3, “a blood vessel a wound” should read --a blood vessel, a wound--.

In column 18, line 28, “agent In” should read --agent. In--.

In column 18, line 40, “inhibitor; or” should read --inhibitor, or--.

In column 18, line 54, “issue” should read --tissue--.

In column 19, line 28, “mammalian issues” should read --mammalian tissues--.

In column 19, line 56, “inhibitors to cuts” should read --inhibitors cuts--.

In column 20, lines 19-20, “immnnolocalized” should read --immunolocalized--.

In column 20, line 56, “amid” should read --aminopterin--.

In column 20, line 60, “supeunatant” should read --supernatant--.

In column 21, line 21, “Immunology” should read --Immunology--.

In column 21, line 24, “12μM. Affinity” should read --12μM). Affinity--.

In column 22, line 19 (in Table 1), “Orignal” should read --Original--.

In column 22, line 48, “leucyl isoleucyl” should read --leucyl, isoleucyl--.

In column 22, line 52, “glutamnyl” should read --glutamyl--.

In column 24, line 7, “three dimensional” should read --three-dimensional--.

In column 24, line 21, “*Munson*” should read --Munson--.

In column 24, line 21, “Pharmacology Munson” should read --Pharmacology, Munson--.

In column 25, line 1, “described GFP” should read --described for GFP--.

In column 25, line 3, “interest When” should read --interest. When--.

In column 25, line 9, “western blots” should read --Western blots--.

In column 25, lines 44-45, “a defined periods” should read --a defined period--.

In column 26, line 12, “characteization” should read --characterization--.

In column 26, line 54, “such other primates” should read --such as other primates--.

In column 27, line 2, “Marinastat” should read --Marimastat--.

In column 27, line 35, “sublingual oral” should read --sublingual, oral--.

In column 27, line 54, “mirocapsules” should read --microcapsules--.

In column 27, line 60, “intra-arterial intramuscular” should read --intra-arterial, intramuscular--.

In column 30, line 9, “Non-queous” should read --Non-aqueous--.

In column 30, line 60, “press” should read --Press--.

In column 30, line 64, “effect” should read --affect--.

In column 31, line 5, “1988);” should read --1988;--.

In column 31, line 6, “1989);” should read --1989;--.

In column 31, line 37, “trascutaneous” should read --transcutaneous--.

In column 32, line 3, “ad administered” should read --administered”.

In column 32, line 9, “admniistered” should read --administered--.

In column 33, lines 66-67, “peptido-encoding” should read --peptide-encoding--.

In column 34, line 49, “100μl mouse” should read --100μl per mouse--.

In column 34, line 53, “placed an eppendorf” should read --placed in an Eppendorf--.

In column 35, line 46, “13 day-old” should read --13-day-old--.

In column 35, line 62, “DLVAA” should read --DIVAA--.

In column 35, line 63, “Am. J.” should read --Am. J.--.

In column 35, line 64, “143 1-1439” should read --1431-1439--.

In column 36, line 16, “ATTC” should read --ATCC--.

In column 36, line 26, “molecular” should read --Molecular--.

In column 37, line 24, “reaction” should read --reaction.--.

In column 37, line 42-45, “PGDF” should read --PDGF--.

In column 37, line 57, “19” should read --19)--.

In column 37, line 59, “18 5 RNA” should read --18 S RNA--.

In column 38, line 32, “Am. J.” should read --Am. J.--.

In column 38, lines 45-46, “compared to and VEGF” should read --compared to AM and VEGF--.

In column 38, line 62, “20 19-2028” should read --2019-2028--.

In column 39, line 21-23, “their effects on growth were compared (FIG. 6A), migration (FIG 6B), and cord formation (FIG 6C).” should read -- their effects on growth (FIG. 6A), migration (FIG 6B), and cord formation (FIG 6C) were compared--.

In column 39, line 57, “undistinguishable” should read --indistinguishable--.

In column 40, line 43, “(12~20)” should read --(12-20)--.

In column 41, line 3, “inamunoassay” should read --immunoassay--.

In column 41, line 9, “Ophthalmol.” should read --Ophthalmol.--.

In column 42, line 16, “Ophthalmol.” should read --Ophthalmol.--.

Since not all of the errors are attributable to the Patent Office, the fee of \$100.00 pursuant to 37 C.F.R. 1.20(a) is submitted herewith via EFS. The Certificate of Correction is enclosed to make formal notice of the errors in the referenced patent.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Tanya M. Harding/
Tanya M. Harding, Ph.D.
Registration No. 42,630

cc: Docketing

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,462,593

DATED : December 9, 2008

INVENTORS : Cuttitta *et al.*

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Cover:

Page 1, above (*), Field (73) is missing. The name of the Assignee should read --The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services--.

Page 1, Field (56) under FOREIGN PATENT DOCUMENTS, a cited reference is missing, which should read --WO 00/69900 11/2000--.

Page 1, Field (56) under Other Publications, "NH₂-terminal" should read --NH₂-terminal--.

Page 1, Field (56) under Other Publications, "Gelatinases" should read -- Gelatinases--.

Page 2, Field (56) under Other Publications, "Adrenomedulling" should read --Adrenomedullin--.

In the Specification:

In column 2, lines 34-35, "for use in treating retinopathy" is a repeated phrase that should be deleted.

In column 3, line 19, "p<0.001" should read --p<0.001--.

In column 3, line 47, "0.01p>0.001" should read --0.01>p>0.001--.

In column 3, line 56, "angiogenesis" should read --angiogenesis--.

In column 4, lines 35-41, "PGDF" should read --PDGF--.

In column 4, lines 42-43, "18 S RNA" should read --18 S RNA--.

In column 4, line 42, "prier" should read --primer--.

In column 6, line 2, "Ophthalmol." should read --Ophthalmol--.

In column 7, line 39, "compliment" should read --complement--.

In column 7, line 51, "complimentary" should read --complementary--.

In column 7, line 56, "membrances" should read --membranes--.

In column 8, line 19, "arthritis considered" should read --arthritis is considered--.

In column 9, line 27, "tansyocardial" should read --transmyocardial--.

MAILING ADDRESS OF SENDER:
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204

PATENT NO. 7,462,593
No. of add'l copies _____
(@ .30 per page)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,462,593

DATED : December 9, 2008

INVENTORS : Cuttitta *et al.*

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 10, line 41, "defect Particular" should read --defect. Particular--.

In column 11, line 7, "Ophthalmol." should read --Ophthalmol.--.

In column 11, line 31, "separated produced" should read --separated, produced--.

In column 11, line 41, "term Thus" should read --term. Thus--.

In column 11, line 60, "and death and death" should read --and death--.

In column 12, line 35, "deoxyribose) linked" should read --deoxyribose)) linked--.

In column 13, line 20, "VFGF" should read --VEGF--.

In column 13, line 43, "mannitol lactose" should read --mannitol, lactose--.

In column 13, line 54, "neoplasm "Treatment"" should read --neoplasm.

"Treatment"--.

In column 14, lines 59-60, "dot-hike" should read --dot-like--.

In column 15, line 49, "Altschnul" should read --Altschul--.

In column 16, line 42, "advancements" should read --advancement--.

In column 16, line 48, "body weight The" should read --body weight. The--.

In column 16, line 63, "disulphide" should read --disulfide--.

In column 18, lines 2-3, "a blood vessel a wound" should read --a blood vessel,
a wound--.

In column 18, line 28, "agent In" should read --agent. In--.

In column 18, line 40, "inhibitor; or" should read --inhibitor, or--.

In column 18, line 54, "issue" should read --tissue--.

In column 19, line 28, "mammalian issues" should read --mammalian tissues--.

In column 19, line 56, "inhibitors to cuts" should read --inhibitors cuts--.

In column 20, lines 19-20, "immnnolocalized" should read --immunolocalized--.

In column 20, line 56, "amid" should read --aminopterin--.

In column 20, line 60, "supeunatant" should read --supernatant--.

In column 21, line 21, "Immunology" should read --Immunology--.

In column 21, line 24, "12μM. Affinity" should read --12μM). Affinity--.

MAILING ADDRESS OF SENDER:
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204

PATENT NO. 7,462,593
No. of add'l copies _____
(@ .30 per page)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,462,593

DATED : December 9, 2008

INVENTORS : Cuttitta *et al.*

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 22, line 19 (in Table 1), "Original" should read --Original--.

In column 22, line 48, "leucyl isoleucyl" should read --leucyl, isoleucyl--.

In column 22, line 52, "glutamnyl" should read --glutamyl--.

In column 24, line 7, "three dimensional" should read --three-dimensional--.

In column 24, line 21, "*Munson*" should read --Munson--.

In column 24, line 21, "Pharmacology Munson" should read --Pharmacology,

Munson--

In column 25, line 1, "described GFP" should read --described for GFP--.

In column 25, line 3, "interest When" should read --interest. When--.

In column 25, line 9, "western blots" should read --Western blots--.

In column 25, lines 44-45, "a defined periods" should read --a defined period--.

In column 26, line 12, "characteization" should read --characterization--.

In column 27, line 2, "Marinastat" should read --Marimastat--.

In column 27, line 35, "sublingual oral" should read --sublingual, oral--.

In column 27, line 54, "mirocapsules" should read --microcapsules--.

In column 27, line 60, "intra-arterial intramuscular" should read --intra-arterial, intramuscular--.

In column 30, line 9, "Non-queueous" should read --Non-aqueous--.

In column 30, line 60, "press" should read --Press--.

In column 30, line 64, "effect" should read --affect--.

In column 31, line 5, "1988);" should read --1988;--.

In column 31, line 6, "1989);" should read --1989;--.

In column 31, line 37, "trascutaneous" should read --transcutaneous--.

In column 32, line 3, "ad administered" should read --administered."

In column 32, line 9, "admniistered" should read --administered--.

In column 33, lines 66-67, "peptido-encoding" should read --peptide-encoding--.

In column 34, line 49, "100µl mouse" should read --100µl per mouse--.

MAILING ADDRESS OF SENDER:
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204

PATENT NO. 7,462,593
No. of add'l copies _____
(@ .30 per page)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,462,593

DATED : December 9, 2008

INVENTORS : Cuttitta *et al.*

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 34, line 53, "placed an eppendorf" should read --placed in an Eppendorf--.

In column 35, line 46, "13 day-old" should read --13-day-old--.

In column 35, line 62, "DLVAA" should read --DIVAA--.

In column 35, line 63, "Am. J." should read --Am. J.--.

In column 35, line 64, "143 1-1439" should read --1431-1439--.

In column 36, line 16, "ATTC" should read --ATCC--.

In column 36, line 26, "molecular" should read --Molecular--.

In column 37, line 24, "reaction" should read --reaction.--.

In column 37, line 42-45, "PGDF" should read --PDGF--.

In column 37, line 57, "19" should read --19)--.

In column 37, line 59, "18 5 RNA" should read --18 S RNA--.

In column 38, line 32, "Am. J." should read --Am. J.--.

In column 38, lines 45-46, "compared to and VEGF" should read --compared to AM and VEGF--.

In column 38, line 62, "20 19-2028" should read --2019-2028--.

In column 39, line 21-23, "their effects on growth were compared (FIG. 6A), migration (FIG 6B), and cord formation (FIG 6C)." should read -- their effects on growth (FIG. 6A), migration (FIG 6B), and cord formation (FIG 6C) were compared--.

In column 39, line 57, "undistinguishable" should read --indistinguishable--.

In column 40, line 43, "(12~20)" should read --(12-20)--.

In column 41, line 3, "inamunoassay" should read --immunoassay--.

In column 41, line 9, "Ophthalmol." should read --Ophthalmol.--.

In column 42, line 16, "Ophthalmol." should read --Ophthalmol.--.

MAILING ADDRESS OF SENDER:
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204

PATENT NO. 7,462,593
No. of add'l copies _____
(@ .30 per page)